RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat and free cash flow fell 94.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow RXST
RxSight, Inc. (RXST) Altman Z-score
RxSight, Inc.'s Altman Z-score for fiscal 2025 is 5.03, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 5.03 | (14.79) |
| FY2024 | 19.81 | (13.75) |
| FY2023 | 33.56 | 35.29 |
| FY2022 | −1.73 | (0.18) |
| FY2021 | −1.55 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.84 | — | 1.01 | |
| Retained earnings / total assets | (2.12) | — | −2.97 | |
| EBIT / total assets | (0.15) | — | −0.51 | |
| Market value of equity / total liabilities | 11.78 | — | 7.07 | |
| Sales / total assets | 0.43 | — | 0.43 | |
| Altman Z-score | Safe zone | 5.03 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 5.56 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ELMD Electromed, Inc. compare | 20.3× |
| PROF Profound Medical compare | 7.3× |
| RXST RxSight, Inc. | 5.0× |
| INGN Inogen, Inc compare | 1.6× |
| CATX Perspective Therapeutics, Inc. compare | −0.6× |
| LAB Standard BioTools Inc. compare | −0.8× |
| QTRX Quanterix Corporation compare | −0.9× |
| STIM Neuronetics, Inc. compare | −3.5× |
| TLSI TriSalus Life Sciences, Inc. compare | −11.3× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets